ARQT
NasdaqARCUTIS BIOTHERAPEUTICS, INC.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$0
2021
$3.7M
2022
$29.2M
2023
$166.5M
2024
$372.1M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$372.1M
Net Income$-16.1M
Gross Profit—
Oper Income$-12.2M
EPS (dil)$-0.13
Rev/sh$2.97
FCF/sh$-0.05
Book/sh$1.51
Gross M—
Oper M-3.3%
Profit M-4.3%
FCF M-1.7%
ROE-8.5%
ROA-3.7%
ROIC-5.1%
R&D/Rev20.7%
Rev Y/Y123.4%
Rev 3Y CAGR365.6%
EPS Y/Y88.8%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+5.2%
Current Ratio3.17
Quick Ratio2.99
Debt/Eq0.58
Int Coverage-1.0×
Net Debt$66.7M
Total Debt$110.0M
Cash & Eq$43.2M
Total Assets$433.0M
Oper CF$-5.6M
Capex$686,000
Free CF$-6.3M
Buybacks—
Equity$189.5M
Liabilities$243.5M
Shs Outstand0.13B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $3.7M | $29.2M | $166.5M | $372.1M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-206.5M | $-301.6M | $-241.1M | $-128.4M | $-12.2M |
| Net Income | $-206.4M | $-311.5M | $-262.1M | $-140.0M | $-16.1M |
| Diluted EPS | $-4.18 | $-5.66 | $-3.78 | $-1.16 | $-0.13 |
| Operating Cash Flow | $-174.6M | $-257.7M | $-247.1M | $-112.2M | $-5.6M |
| Free Cash Flow | $-175.6M | $-258.0M | $-247.5M | $-112.3M | $-6.3M |
COMMUNITY · $ARQT0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.